Stephanie Lovell Sells 1,193 Shares of TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director Stephanie Lovell sold 1,193 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $149.62, for a total value of $178,496.66. Following the completion of the sale, the director owned 2,866 shares of the company’s stock, valued at approximately $428,810.92. This trade represents a 29.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

TransMedics Group Price Performance

TransMedics Group stock opened at $129.80 on Friday. The firm has a market cap of $4.45 billion, a PE ratio of 26.49 and a beta of 1.98. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 6.59. The stock’s fifty day moving average price is $135.35 and its two-hundred day moving average price is $126.93. TransMedics Group, Inc. has a one year low of $62.23 and a one year high of $156.00.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TMDX. Morgan Stanley raised their price target on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Piper Sandler upped their price objective on shares of TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. increased their price objective on shares of TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Needham & Company LLC raised their target price on shares of TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, Oppenheimer boosted their target price on shares of TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $150.67.

Institutional Investors Weigh In On TransMedics Group

Hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP increased its position in TransMedics Group by 258.7% during the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after purchasing an additional 394,340 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in TransMedics Group by 50.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after buying an additional 322,353 shares in the last quarter. Two Sigma Investments LP grew its stake in shares of TransMedics Group by 54.2% during the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after buying an additional 223,409 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of TransMedics Group by 100.5% during the fourth quarter. Wellington Management Group LLP now owns 433,321 shares of the company’s stock worth $52,713,000 after buying an additional 217,180 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of TransMedics Group by 43.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock worth $69,338,000 after buying an additional 171,810 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.